Related Experiment Video
Updated: Aug 24, 2026

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives
Antti Mäntylä1, Jarkko Rautio, Tapio Nevalainen
1Department of Pharmaceutical Chemistry, University of Kuopio, Finland. antti.mantyla@pp2.inet.fi
Abstract:
Novel oxime derivatives (2, 3 and 5) of buparvaquone (1) and O-methyl-buparvaquone (4) were synthesized and their in vitro activities against Leishmania donovani, the causative agent of visceral leishmaniasis (VL), were determined. Buparvaquone-oxime (2) was also studied as a bioreversible prodrug structure of buparvaquone (1). Buparvaquone-oxime (2) released buparvaquone (1) in vitro when it was incubated with induced rat liver microsomes, which suggests that the oxime-structure is a useful prodrug template for developing novel prodrugs of buparvaquone and other hydroxynaphthoquinones. Moreover, the formation of NO(2)(-) , formed via oxidation of NO, was confirmed during the bioconversion. The release of NO from buparvaquone-oxime (2) may provide an additional therapeutic effect in the treatment of leishmaniasis. Buparvaquone-oxime (2) and buparvaquone-O-methyloxime (3) demonstrated moderate activity against amastigotes of the Leishmania species that causes VL. However, the studied oximes (2, 3) most probably did not release buparvaquone (1) and NO during the present in vitro experiment. Further in vivo studies are needed to verify the biological activity of buparvaquone-oximes in the treatment of leishmaniasis.
Related Concept Videos
Antiprotozoal Agents
Anthelminthic Agents
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Antiviral Nucleoside Inhibitors
Antifungal Agents
Diazonium Group Substitution: –OH and –H
